Mechanisms of resveratrol-induced inhibition of clonal expansion and terminal adipogenic differentiation in 3T3-L1 preadipocytes

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 68, Issue 11, 2013, Pages 1356-1376

  Mitterberger, Maria C ^a   Zwerschke, Werner ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

3T3 L1 preadipocytes; AKT; AMPK; Caloric restriction; cdki; Cyclin D1; MAPK; PGC1 ; PPAR 2; Resveratrol; Retinoblastoma protein; Sirt1

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHROMAN DERIVATIVE; CYCLIN D1; FABP4 PROTEIN, MOUSE; FATTY ACID BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NAPHTHALENE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PYRONE DERIVATIVE; RESVERATROL; RETINOBLASTOMA PROTEIN; SPLITOMICIN; STILBENE DERIVATIVE; TROGLITAZONE;

3T3-L1 PREADIPOCYTES; ADIPOCYTE; AKT; AMPK; ANIMAL; ARTICLE; BIOSYNTHESIS; CALORIC RESTRICTION; CDKI; CELL DIFFERENTIATION; CELL STRAIN 3T3; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; MAPK; METABOLISM; MOUSE; PGC1Α; PHYSIOLOGY; PPARΓ2; SIRT1; STEM CELL; 3T3 CELL LINE; DRUG EFFECTS;

3T3-L1 PREADIPOCYTES; AKT; AMPK; CALORIC RESTRICTION; CDKI; CYCLIN D1; MAPK; PGC1Α; PPARΓ2; RESVERATROL; RETINOBLASTOMA PROTEIN; SIRT1;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; CHROMANS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FATTY ACID-BINDING PROTEINS; GENE EXPRESSION REGULATION; MICE; NAPHTHALENES; PPAR GAMMA; PYRONES; STEM CELLS; STILBENES; THIAZOLIDINEDIONES;

EID: 84886052315     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glt019     Document Type: Article

References (96)

1. Bishop NA, Guarente L. Genetic links between diet and lifespan: shared mechanisms from yeast to humans. Nat Rev Genet. 2007; 8:835-844.
2. Rochon J, Bales CW, Ravussin E, et al. Design and conduct of the CALERIE study: comprehensive assessment of the long-term effects of reducing intake of energy. J Gerontol A Biol Sci Med Sci. 2011;66:97-108.
3. Haslam DW, James WP. Obesity. Lancet. 2005;366:1197-1209.
4. Di Nisio M, Di Iorio A, Porreca E, et al. Obesity, poor muscle strength, and venous thromboembolism in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2011;66:320-325.
5. Stenholm S, Sallinen J, Koster A, et al. Association between obesity history and hand grip strength in older adults-Exploring the roles of inflammation and insulin resistance as mediating factors. J Gerontol A Biol Sci Med Sci. 2011;66:341-348.
6. Le Couteur DG, McLachlan AJ, Quinn RJ, Simpson SJ, de Cabo R. Aging biology and novel targets for drug discovery. J Gerontol A Biol Sci Med Sci. 2012;67:168-174.
7. Smoliga JM, Vang O, Baur JA. Challenges of translating basic research into therapeutics: resveratrol as an example. J Gerontol A Biol Sci Med Sci. 2012;67:158-167.
8. Serazetdinova L, Oldach KH, Lorz H. Expression of transgenic stilbene synthases in wheat causes the accumulation of unknown stilbene derivatives with antifungal activity. J Plant Physiol. 2005;162: 985-1002.
9. Arichi H, Kimura Y, Okuda H, Baba K, Kozawa M, Arichi S. Effects of stilbene components of the roots of Polygonum cuspidatum Sieb. et Zucc. on lipid metabolism. Chem Pharm Bull. 1982;30:1766-1770.
10. Farina A, Ferranti C, Marra C. An improved synthesis of resveratrol. Nat Prod Res. 2006;20:247-252.
11. Siemann E, Creasy L. Concentration of the phytoalexin resveratrol in wine. Am J Eno Vitic. 1992;43:49-52.
12. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta. 1995;235:207-219.
13. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275:218-220.
14. Kim D, Nguyen MD, Dobbin MM, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 2007;26:3169-3179.
15. Pearson KJ, Baur JA, Lewis KN, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008;8:157-168.
16. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127:1109-1122.
17. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337-342.
18. Pirola L, Frojdo S. Resveratrol: one molecule, many targets. IUBMB Life. 2008;60:323-332.
19. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14:612-622.
20. Crandall JP, Oram V, Trandafirescu G, et al. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci. 2012;67:1307-1312.
21. Dai Z, Li Y, Quarles LD, et al. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine. 2007;14: 806-814.
22. Bernhard D, Tinhofer I, Tonko M, et al. Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells. Cell Death Differ. 2000;7:834-842.
23. Zhang J. Resveratrol inhibits insulin responses in a SirT1-independent pathway. Biochem J. 2006;397:519-527.
24. Ahmad KA, Clement MV, Hanif IM, Pervaiz S. Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution. Cancer Res. 2004;64:1452-1459.
25. MacCarrone M, Lorenzon T, Guerrieri P, Agro AF. Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem. 1999;265:27-34.
26. Liu W, Hong Q, Bai XY, et al. High-affinity Na(+)-dependent dicarboxylate cotransporter promotes cellular senescence by inhibiting SIRT1. Mech Ageing Dev. 2010;131:601-613.
27. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425:191-196.
28. Wood JG, Rogina B, Lavu S, et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature. 2004;430:686-689.
29. Kaeberlein M, McDonagh T, Heltweg B, et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem. 2005;280:17038-17045.
30. Allard JS, Perez E, Zou S, de Cabo R. Dietary activators of Sirt1. Mol Cell Endocrinol. 2009;299:58-63.
31. Canto C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458:1056-1060.
32. Venkatesan B, Ghosh-Choudhury N, Das F, et al. Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: role of PTP1B. FASEB J. 2008;22:3469-3482.
33. Frojdo S, Cozzone D, Vidal H, Pirola L. Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem J. 2007;406:511-518.
34. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J. 2003;17:1975-1985.
35. Allison DB, Miller RA, Austad SN, et al. Genetic variability in responses to caloric restriction in animals and in regulation of metabolism and obesity in humans. J Gerontol A Biol Sci Med Sci. 2001;56 Spec No 1:55-65.
36. Bertrand HA, Lynd FT, Masoro EJ, Yu BP. Changes in adipose mass and cellularity through the adult life of rats fed ad libitum or a lifeprolonging restricted diet. J Gerontol. 1980;35:827-835.
37. Liao CY, Rikke BA, Johnson TE, Gelfond JA, Diaz V, Nelson JF. Fat maintenance is a predictor of the murine lifespan response to dietary restriction. Aging Cell. 2011;10:629-639.
38. Bluher M. Fat tissue and long life. Obes Facts. 2008;1:176-182.
39. Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature. 2004;429:771-776.
40. Drolet R, Richard C, Sniderman AD, et al. Hypertrophy and hyperplasia of abdominal adipose tissues in women. Int J Obes (Lond). 2008;32:283-291.
41. Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. Nature. 2008;453:783-787.
42. Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to its source. Cell. 2007;131:242-256.
43. Green H, Kehinde O. An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion. Cell. 1975;5:19-27.
44. Farmer SR. Transcriptional control of adipocyte formation. Cell Metab. 2006;4:263-273.
45. Cao Z, Umek RM, McKnight SL. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev. 1991;5:1538-1552.
46. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994;8:1224-1234.
47. Wu Z, Xie Y, Bucher NL, Farmer SR. Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis. Genes Dev. 1995;9:2350-2363.
48. Rainer J, Sanchez-Cabo F, Stocker G, Sturn A, Trajanoski Z. CARMAweb: comprehensive R-and bioconductor-based web service for microarray data analysis. Nucleic Acids Res. 2006;34(Web Server issue):W498-W503.
49. Spoden GA, Mazurek S, Morandell D, et al. Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int J Cancer. 2008;123: 312-321.
50. Rozen S. SH Primer3 on the www for general users and for biologist programmers. In: Krawetz SA, Misener S, eds. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa, NJ: Humana Press; 2000.
51. Massague J, Gomis RR. The logic of TGFbeta signaling. FEBS Lett. 2006;580:2811-2820.
52. Burton GR, Nagarajan R, Peterson CA, McGehee RE Jr. Microarray analysis of differentiation-specific gene expression during 3T3-L1 adipogenesis. Gene. 2004;329:167-185.
53. Morrison RF, Farmer SR. Role of PPARγ in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis. J Biol Chem. 1999;274: 17088-17097.
54. Hofmann TG, Moller A, Sirma H, et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol. 2002;4:1-10.
55. Hollander MC, Alamo I, Jackman J, Wang MG, McBride OW, Fornace AJ Jr. Analysis of the mammalian gadd45 gene and its response to DNA damage. J Biol Chem. 1993;268:24385-24393.
56. Canistro D, Bonamassa B, Pozzetti L, et al. Alteration of xenobiotic metabolizing enzymes by resveratrol in liver and lung of CD1 mice. Food Chem Toxicol. 2009;47:454-461.
57. Ciolino HP, Yeh GC. Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol. 1999;56:760-767.
58. Rayalam S, Della-Fera MA, Yang JY, Park HJ, Ambati S, Baile CA. Resveratrol potentiates genistein's antiadipogenic and proapoptotic effects in 3T3-L1 adipocytes. J Nutr. 2007;137:2668-2673.
59. DeGregori J. The Rb network. J Cell Sci. 2004;117(Pt 16):3411-3413.
60. Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov. 2012;11:443-461.
61. Rayalam S, Yang JY, Ambati S, Della-Fera MA, Baile CA. Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother Res. 2008;22:1367-1371.
62. Lamb J, Ramaswamy S, Ford HL, et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 2003;114:323-334.
63. Wang C, Pattabiraman N, Zhou JN, et al. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol. 2003;23:6159-6173.
64. Rosen JM. Striking it rich by data mining. Cell. 2003;114:271-272.
65. Qin C, Burghardt R, Smith R, Wormke M, Stewart J, Safe S. Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res. 2003;63:958-964.
66. Otto TC, Lane MD. Adipose development: from stem cell to adipocyte. Crit Rev Biochem Mol Biol. 2005;40:229-242.
67. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799-806.
68. Hawley SA, Ross FA, Chevtzoff C, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 2010;11:554-565.
69. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011;25:1895-1908.
70. Kajimura S, Seale P, Spiegelman BM. Transcriptional control of brown fat development. Cell Metab. 2010;11:257-262.
71. Rodgers JT, Lerin C, Gerhart-Hines Z, Puigserver P. Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett. 2008;582:46-53.
72. Karamanlidis G, Karamitri A, Docherty K, Hazlerigg DG, Lomax MA. C/EBPbeta reprograms white 3T3-L1 preadipocytes to a Brown adipocyte pattern of gene expression. J Biol Chem. 2007;282:24660-24669.
73. Verdin E, Hirschey MD, Finley LW, Haigis MC. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci. 2010;35:669-675.
74. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004;23:2369-2380.
75. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001;107:149-159.
76. Mader I, Wabitsch M, Debatin KM, Fischer-Posovszky P, Fulda S. Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis. FASEB J. 2010;24:1997-2009.
77. Baile CA, Yang JY, Rayalam S, et al. Effect of resveratrol on fat mobilization. Ann N Y Acad Sci. 2011;1215:40-47.
78. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-ordeath switch. Nat Rev Cancer. 2002;2:647-656.
79. Yang JY, Della-Fera MA, Rayalam S, et al. Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci. 2008;82:1032-1039.
80. Worster DT, Schmelzle T, Solimini NL, et al. AKT and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2. Sci Signal. 2012;5:ra19.
81. Weber JD, Raben DM, Phillips PJ, Baldassare JJ. Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem J. 1997;326:61-68.
82. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12:3499-3511.
83. Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res. 2002;8:893-903.
84. Wang Z, Chen Y, Labinskyy N, Hsieh TC, Ungvari Z, Wu JM. Regulation of proliferation and gene expression in cultured human aortic smooth muscle cells by resveratrol and standardized grape extracts. Biochem Biophys Res Commun. 2006;346:367-376.
85. Csiszar A, Labinskyy N, Pinto JT et al. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol. 2009; 297:H13-H20.
86. Kim SH, Park HS, Lee MS, et al. Vitisin A inhibits adipocyte differentiation through cell cycle arrest in 3T3-L1 cells. Biochem Biophys Res Commun. 2008;372:108-113.
87. Qiu Z, Wei Y, Chen N, Jiang M, Wu J, Liao K. DNA synthesis and mitotic clonal expansion is not a required step for 3T3-L1 preadipocyte differentiation into adipocytes. J Biol Chem. 2001;276:11988-11995.
88. Tang QQ, Otto TC, Lane MD. Mitotic clonal expansion: a synchronous process required for adipogenesis. Proc Natl Acad Sci USA. 2003;100:44-49.
89. Bluher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science. 2003;299:572-574.
90. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science. 1996;274:2100-2103.
91. rd, Arden KC, Accili D. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev Cell. 2003;4:119-129.
92. De Pauw A, Tejerina S, Raes M, Keijer J, Arnould T. Mitochondrial (dys)function in adipocyte (de)differentiation and systemic metabolic alterations. Am J Pathol. 2009;175:927-939.
93. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev. 2006;27:728-735.
94. Hondares E, Mora O, Yubero P, et al. Thiazolidinediones and rexinoids induce peroxisome proliferator-activated receptor-coactivator (PGC)-1alpha gene transcription: an autoregulatory loop controls PGC-1alpha expression in adipocytes via peroxisome proliferator-activated receptor-gamma coactivation. Endocrinology. 2006;147:2829-2838.
95. Zang Y, Yu LF, Nan FJ, Feng LY, Li J. AMP-activated protein kinase is involved in neural stem cell growth suppression and cell cycle arrest by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and glucose deprivation by down-regulating phospho-retinoblastoma protein and cyclin D. J Biol Chem. 2009;284:6175-6184.
96. Daval M, Foufelle F, Ferre P. Functions of AMP-activated protein kinase in adipose tissue. J Physiol (Lond). 2006;574(Pt 1):55-62.